ArticleFrontiers in oncology2026
Clinical diagnostic value of serum CEA and CA19-9 in patients with advanced pancreatic cancer: A prognostic cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical diagnostic value of serum tumor markers (CEA and CA19‑9) and other blood‑based indicators in patients with advanced pancreatic cancer, and to assess their prognostic significance. Methods: A retrospective analysis of 136 patients with advanced pancreatic cancer was conducted. Preoperative blood test results and peripheral immune cell counts, clinical characteristics, and survival data were collected. Univariate and multivariate Cox regression analyses were performed, and overall survival (OS) was assessed using the Kaplan-Meier method. Results: ROC analysis showed good diagnostic accuracy for CA19‑9 (AUC = 0.886; optimal cutoff 37.44 U/mL) and CEA (AUC = 0.858; optimal cutoff 7.16 ng/mL). During follow‑up, 98 deaths occurred. Univariate analysis identified lymph node metastasis, elevated LDH, ALP, CA19‑9, CEA, CA125, CRP, NLR, and decreased LMR and albumin as significant risk factors for OS. Multivariate analysis revealed that elevated CA19‑9 (HR = 2.059, 95% CI: 1.185-3.576, Conclusions: Preoperative serum CA19‑9 is an independent prognostic factor and a valuable diagnostic biomarker in advanced pancreatic cancer. CEA shows diagnostic potential but is not an independent prognostic factor after adjusting for CA19‑9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.